Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Platelet-Rich Plasma and Combination Therapies for Dry Eye Disease: Current Advances and Future Directions

Liu Y., Liu J., Cao R.

Narrative Review on Chronic Inflammation, published in Transfus Med Hemother (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Transfus Med Hemother (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41409646
PMCID
PMC12707939
DOI
10.1159/000549202
Citations
1

Abstract (original English)

Background Dry eye disease (DED), as one of the most prevalent ocular surface diseases, is a multifactorial disorder disrupting tear film homeostasis and ocular surface integrity, profoundly impacts patients' quality of life. Conventional therapies such as artificial tears and anti-inflammatory agents provide transient relief but fail to address underlying pathological mechanisms and may induce complications with prolonged use. Summary Platelet-rich plasma (PRP), an autologous biologic agent enriched with growth factors (e.g., platelet-derived growth factor, transforming growth factor-β, epidermal growth factor), has emerged as a promising therapeutic strategy. PRP promotes corneal epithelial regeneration, reduces inflammation, and restores glandular function, offering a pathophysiologically targeted approach. Recent studies highlight synergistic benefits of combining PRP with agents like hyaluronic acid, stem cells, or nanomaterials, which enhance tear film stability and tissue repair. Despite encouraging preclinical and clinical outcomes, optimal protocols and long-term safety of PRP-based combination therapies remain under investigation. Key messages This review synthesizes current evidence on PRP's mechanisms, clinical efficacy, and innovative combinatorial approaches for DED, emphasizing the need for standardized trials to validate these strategies. Future integration of P

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research